Generic competition · all medicines · read 12 November 2026
Is there a generic of Triamcinolone Acetonide, and who makes it?
Triamcinolone Acetonide appears in 14 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 30 generic makers listed as marketed across them. 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 9.5 and 21.6 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Triamcinolone Acetonide appears in 14 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 30 generic makers listed as marketed across them.
- 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 9.5 and 21.6 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Cream, Topical
Four or more generic makers listed
Every brand product here is listed as discontinued. 10 generic makers with 24 generic products listed as marketed; the first generic approval is dated 4 June 1982.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Fougera Pharmaceuticals Inc | not dated | 3 |
| Padagis Us Llc | not dated | 3 |
| Crown Laboratories Inc | 19 March 1984 | 3 |
| Cosette Pharmaceuticals Nc Laboratories Llc | 31 May 1991 | 2 |
| Taro Pharmaceutical Industries Ltd | 26 November 1997 | 1 |
| Micro Labs Ltd | 9 June 2006 | 2 |
| Chartwell Rx Sciences Llc | 1 February 2017 | 3 |
| Encube Ethicals Private Ltd | 18 September 2017 | 1 |
| Alkem Laboratories Ltd | 26 December 2017 | 3 |
| Macleods Pharmaceuticals Ltd | 18 May 2018 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Ointment, Topical
Four or more generic makers listed
Every brand product here is listed as discontinued. 10 generic makers with 20 generic products listed as marketed; the first generic approval is dated 7 June 1982.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Fougera Pharmaceuticals Inc | not dated | 3 |
| Padagis Us Llc | not dated | 3 |
| Cosette Pharmaceuticals Nc Laboratories Llc | 23 December 1988 | 2 |
| Sun Pharma Canada Inc | 30 September 1994 | 1 |
| Encube Ethicals Private Ltd | 13 May 2016 | 2 |
| Chartwell Rx Sciences Llc | 12 October 2018 | 2 |
| Macleods Pharmaceuticals Ltd | 23 November 2018 | 4 |
| Strides Pharma Global Pte Ltd | 1 June 2020 | 1 |
| Pharmazone | 10 November 2020 | 1 |
| Padagis Israel Pharmaceuticals Ltd | 5 February 2021 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Lotion, Topical
Four or more generic makers listed
Every brand product here is listed as discontinued. 6 generic makers with 10 generic products listed as marketed; the first generic approval is dated 8 September 1982.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Pharmobedient Consulting Llc | 1 April 1985 | 2 |
| Cosette Pharmaceuticals Nc Laboratories Llc | 14 August 1986 | 1 |
| Fougera Pharmaceuticals Inc | 21 April 2003 | 2 |
| Micro Labs Ltd | 13 December 2006 | 1 |
| Epic Pharma Llc | 8 May 2013 | 2 |
| Quagen Pharmaceuticals Llc | 1 July 2020 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Four or more generic makers listed
Brand listed as marketed: Kenalog-10, Kenalog-40 and Kenalog-80. 8 generic makers with 9 generic products listed as marketed; the first generic approval is dated 27 May 2009.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Amneal Eu Ltd | 11 December 2017 | 1 |
| Teva Pharmaceuticals Usa Inc | 5 October 2018 | 1 |
| Long Grove Pharmaceuticals Llc | 19 January 2022 | 1 |
| Eugia Pharma Specialities Ltd | 5 July 2022 | 1 |
| Mylan Laboratories Ltd | 2 November 2022 | 1 |
| Hikma Pharmaceuticals Usa Inc | 9 December 2024 | 1 |
| Dr Reddys Laboratories Ltd | 12 March 2025 | 2 |
| Alembic Pharmaceuticals Ltd | 17 October 2025 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Paste, Dental
Four or more generic makers listed
Every brand product here is listed as discontinued. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 1 October 1986.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Sun Pharma Canada Inc | 1 October 1986 | 1 |
| Rising Pharma Holdings Inc | 1 July 2010 | 1 |
| Cosette Pharmaceuticals Nc Laboratories Llc | 12 January 2017 | 1 |
| Quagen Pharmaceuticals Llc | 9 December 2022 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Spray, Metered, Nasal
One to three generic makers listed
Brand listed as marketed: Nasacort Allergy 24 Hour. 3 generic makers with 3 generic products listed as marketed; the first generic approval is dated 30 July 2009.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Perrigo Pharma International Dac | 14 November 2014 | 1 |
| Apotex Inc | 19 January 2023 | 1 |
| Aurobindo Pharma Ltd | 11 August 2026 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Spray, Topical
One to three generic makers listed
Every brand product here is listed as discontinued. 3 generic makers with 3 generic products listed as marketed; the first generic approval is dated 13 April 2015.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Padagis Israel Pharmaceuticals Ltd | 13 April 2015 | 1 |
| Sciegen Pharmaceuticals Inc | 7 December 2016 | 1 |
| Rising Pharma Holdings Inc | 8 September 2017 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Aerosol, Metered, Inhalation
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Aerosol, Metered, Nasal
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
For Suspension, Extended Release, Intra-Articular
Brand listed, no generic listed as marketed
Brand listed as marketed: Zilretta. No generic is listed as marketed.
Patents and exclusivities still listed
- 4 August 2031Patent 9555048
- 4 August 2031Patent 8828440 drug product
Gel, Topical
Nothing listed as marketed
No brand application is listed. No generic is listed as marketed (1 generic product listed as discontinued).
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Intra-Articular, Intramuscular, Intravitreal
Nothing listed as marketed
Every brand product here is listed as discontinued. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Intravitreal
Brand listed, no generic listed as marketed
Brand listed as marketed: Triesence. No generic is listed as marketed.
Patents and exclusivities still listed
- 10 March 2029Patent 8211880
- 17 December 2029Patent 8128960 drug product
Suspension, Injection
Brand listed, no generic listed as marketed
Brand listed as marketed: Xipere. No generic is listed as marketed.
Patents and exclusivities still listed
- 2 May 2027Patent 8636713
- 8 November 2033Patent 9636332
- 2 May 2034Patent 9937075 drug product
- 16 April 2040Patent 12419833 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.